Trial Profile
A Double-blind, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two New Insulin Glargine Formulations Using the Euglycemic Clamp Technique in Subjects With Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Sanofi
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 18 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 18 Jul 2013 Planned end date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov record.